[go: up one dir, main page]

EP1223924A4 - Use of csaids in rhinovirus infection - Google Patents

Use of csaids in rhinovirus infection

Info

Publication number
EP1223924A4
EP1223924A4 EP00965060A EP00965060A EP1223924A4 EP 1223924 A4 EP1223924 A4 EP 1223924A4 EP 00965060 A EP00965060 A EP 00965060A EP 00965060 A EP00965060 A EP 00965060A EP 1223924 A4 EP1223924 A4 EP 1223924A4
Authority
EP
European Patent Office
Prior art keywords
csaids
rhinovirus infection
rhinovirus
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00965060A
Other languages
German (de)
French (fr)
Other versions
EP1223924A2 (en
Inventor
Susan B Dillon
Sandra D Griego
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1223924A2 publication Critical patent/EP1223924A2/en
Publication of EP1223924A4 publication Critical patent/EP1223924A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP00965060A 1999-09-17 2000-09-15 Use of csaids in rhinovirus infection Withdrawn EP1223924A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15449499P 1999-09-17 1999-09-17
US154494P 1999-09-17
PCT/US2000/025386 WO2001019322A2 (en) 1999-09-17 2000-09-15 Use of csaids in rhinovirus infection

Publications (2)

Publication Number Publication Date
EP1223924A2 EP1223924A2 (en) 2002-07-24
EP1223924A4 true EP1223924A4 (en) 2004-07-14

Family

ID=22551566

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00965060A Withdrawn EP1223924A4 (en) 1999-09-17 2000-09-15 Use of csaids in rhinovirus infection

Country Status (17)

Country Link
EP (1) EP1223924A4 (en)
JP (1) JP2003516314A (en)
KR (1) KR20020032591A (en)
CN (1) CN1382044A (en)
AR (1) AR025691A1 (en)
AU (1) AU7584500A (en)
BR (1) BR0014041A (en)
CA (1) CA2385722A1 (en)
CO (1) CO5200855A1 (en)
CZ (1) CZ2002939A3 (en)
HU (1) HUP0204333A3 (en)
IL (1) IL148329A0 (en)
NO (1) NO20021301L (en)
PL (1) PL363116A1 (en)
TR (1) TR200200673T2 (en)
WO (1) WO2001019322A2 (en)
ZA (1) ZA200202060B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
JP2002528506A (en) 1998-11-04 2002-09-03 スミスクライン・ビーチャム・コーポレイション Pyridin-4-yl or pyrimidin-4-yl substituted pyrazine
JP2003514899A (en) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション 3,4-Dihydro- (1H) -quinazolin-2-one compounds as CSBP / p38 kinase inhibitors
ES2241675T3 (en) 1999-11-23 2005-11-01 Smithkline Beecham Corporation 3,4-DIHIDRO- (1H) QUINAZOLIN-2-ONA COMPOUNDS AS CSPB / P38 QUINASA INHIBITORS.
EP1233950B1 (en) 1999-11-23 2005-10-05 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
WO2002060869A2 (en) * 2000-10-19 2002-08-08 Smithkline Beecham Corporation Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2002246855B2 (en) 2000-10-23 2005-12-22 Smithkline Beecham Corporation Novel compounds
ES2302925T3 (en) * 2002-03-20 2008-08-01 Elan Pharma International Limited COMPOSITIONS OF NANOPARTICULES OF PROTEIN QUINASA INHIBITORS ACTIVATED BY MYTHOGEN (MAP).
PL372963A1 (en) * 2002-04-05 2005-08-08 Boehringer Ingelheim Pharma Gmb & Co.Kg Method of treating mucus hypersecretion
JP2005538066A (en) * 2002-07-09 2005-12-15 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Novel pharmaceutical composition using novel anticholinergic agent and p38 kinase inhibitor
JP4593953B2 (en) * 2004-03-30 2010-12-08 杏林製薬株式会社 Rhinovirus infection prophylaxis
US20060030550A1 (en) * 2004-08-04 2006-02-09 Lithgow Theodore L Pharmaceutical formulations
AR053346A1 (en) 2005-03-25 2007-05-02 Glaxo Group Ltd COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38
DK2276505T3 (en) * 2008-03-20 2013-11-25 Krister Tano Nose Spray Or Nasal Drops For Treating A Cold
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
CN102573886A (en) * 2009-09-17 2012-07-11 相互制药公司 Method of treating asthma with antiviral agents
GB201010193D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
US11730760B2 (en) 2011-04-01 2023-08-22 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
US11389663B2 (en) 2011-04-01 2022-07-19 Bioregentech, Inc. Laser assisted wound healing protocol and system
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3128468A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
GB201721793D0 (en) * 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
WO2021216754A1 (en) * 2020-04-21 2021-10-28 Spring Discovery, Inc. Use of p38 mapk inhibitors for prevention and treatment of aging and aging-related disorders and for boosting an immune system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
WO2000040243A1 (en) * 1999-01-08 2000-07-13 Smithkline Beecham Corporation Novel compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3927216A (en) * 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
WO2000040243A1 (en) * 1999-01-08 2000-07-13 Smithkline Beecham Corporation Novel compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUJIME K ET AL: "P38 MITOGEN-ACTIVATED PROTEIN KINASE AND C-JUN-NH2-TERMINAL KINASE REGULATE RANTES PRODUCTION BY INFLUENZA VIRUS-INFECTED HUMAN BRONCHIAL EPITHELIAL CELLS", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 164, no. 6, 15 March 2000 (2000-03-15), pages 3222 - 3228, XP001164262, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
NO20021301D0 (en) 2002-03-15
EP1223924A2 (en) 2002-07-24
HUP0204333A3 (en) 2004-07-28
IL148329A0 (en) 2002-09-12
CN1382044A (en) 2002-11-27
TR200200673T2 (en) 2002-12-23
BR0014041A (en) 2003-07-15
HUP0204333A2 (en) 2003-05-28
CA2385722A1 (en) 2001-03-22
WO2001019322A3 (en) 2001-10-04
KR20020032591A (en) 2002-05-03
NO20021301L (en) 2002-05-16
CO5200855A1 (en) 2002-09-27
AR025691A1 (en) 2002-12-11
ZA200202060B (en) 2003-05-28
JP2003516314A (en) 2003-05-13
WO2001019322A2 (en) 2001-03-22
PL363116A1 (en) 2004-11-15
AU7584500A (en) 2001-04-17
CZ2002939A3 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
HUP0204333A3 (en) Use of csaids in rhinovirus infection
GB9915414D0 (en) Medical use
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
PL352330A1 (en) Derivatives of pyridopyranoazepine, making of same and use of same in therapy
IL147503A0 (en) Oxazolidinone compounds and methods of preparation and use thereof
AU4289100A (en) Dihydropyrimidines and their use in the treatment of hepatitis
HU0001396D0 (en) 3-amino-3-arylpropan-1-al derivatives and their use
PL352333A1 (en) Dihydrobenzodiazepines and use of same in treatment of dislipidemia
GB9907965D0 (en) Medical use
EP1161451A4 (en) Human endokine alpha and methods of use
GB9929318D0 (en) Macrocyclic compounds and their use
PL350963A1 (en) Use of arylalkanoylpyridazines
GB0018887D0 (en) Compound and their therapeutic use
AU4116500A (en) The use of alpha lipoic acid in the antimetastatic treatment
GB9922825D0 (en) Medical use
AU3554800A (en) Use of porphyrin derivatives in aquariums
AU2001223910A1 (en) Interferon-alpha use in the treatment of ewing's family of tumors
GB9929581D0 (en) Comjpositions and their use
GB9905307D0 (en) Therapy and use of compounds in therapy
GB9905315D0 (en) Therapy and use of compounds in therapy
GB0012401D0 (en) Treatment of infection in animals
GB0022210D0 (en) Treatment of infection in animals
GB9901904D0 (en) RTherapeutic use of human pheramones
NZ514013A (en) Treatment of hiatial hernia
GB9920996D0 (en) Improvements in the human support of catheter leg-bags

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020328

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI PAYMENT 20020328

A4 Supplementary search report drawn up and despatched

Effective date: 20040603

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/495 B

Ipc: 7A 61K 31/41 B

Ipc: 7A 61K 31/454 B

Ipc: 7A 61K 31/50 B

Ipc: 7A 61K 31/415 B

Ipc: 7A 61K 31/13 A

Ipc: 7A 61K 31/70 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20040629

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1048936

Country of ref document: HK